<DOC>
	<DOCNO>NCT00004533</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine maximum tolerate dose recombinant adeno-associated virus-CFTR vector patient cystic fibrosis . II . Assess safety gene therapy patient . III . Assess vivo gene transfer vector patient . IV . Assess CFTR gene expression physiologic activity follow gene transfer patient . V. Assess clinical impact CFTR gene expression follow gene transfer patient . VI . Monitor patient immune response direct CFTR vector component follow vector administration .</brief_summary>
	<brief_title>Phase I Randomized Study Adeno-Associated Virus-CFTR Vector Patients With Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , dose escalation , double blind , placebo control , multicenter study . Patients randomize receive either adeno-associated virus-CFTR ( AAV-CFTR ) vector placebo . Patients undergo test day -10 -4 rule adenovirus adeno-associated virus infection . Patients receive AAV-CFTR vector intranasally right leave inferior turbinate placebo side nose . The next day , patient receive endobronchial dose AAV-CFTR vector superior segment right low lobe . Cohorts 2-4 patient receive escalate dos AAV-CFTR vector maximum tolerate dose ( MTD ) determine . The MTD define dose level immediately precede dose least 2 subject develop dose limit toxicity . Patients follow day 10 , 1 , 2 , 3 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis cystic fibrosis ( CF ) mild moderate lung disease ; FVC least 60 % predict ; SchwachmanKulczycki score least 65 ; Sweat chloride great 60 mEq/L All CF genotype allow No sputum colonization Burkholderia cepacia another multiply resistant organism No recurrent intermittent hemoptysis ; At least 1 year since significant hemoptysis require transfusion embolization OR Coughing great 30 mL blood often week Prior/Concurrent Therapy At least 30 day since hospitalization home intravenous antibiotic therapy pulmonary exacerbation No concurrent investigational drug therapy Patient Characteristics Other : No concurrent cigarette smoking ; Not pregnant nursing ; Negative pregnancy test ; Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>